Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioCatalytics obtains United States patent.


BioCatalytics, Inc. (Pasadena, CA) has patented methods for chemically transforming compounds using a mutated enzyme, and more particularly a method for the production of an amino acid amino acid (əmē`nō), any one of a class of simple organic compounds containing carbon, hydrogen, oxygen, nitrogen, and in certain cases sulfur. These compounds are the building blocks of proteins.  from a target 2-ketoacid, the production of an amine amine (əmēn`, ăm`ēn): see under amino group.
amine

Any of a class of nitrogen-containing organic compounds derived, either in principle or in practice, from ammonia (NH3).
 from a target ketone ketone (kē`tōn), any of a class of organic compounds that contain the carbonyl group, C=O, and in which the carbonyl group is bonded only to carbon atoms.  and the production of an alcohol from a target ketone. The methods comprise creating a mutated enzyme that catalyzes the reductive amination or transamination Transamination

The transfer of an amino group from one molecule to another without the intermediate formation of ammonia. Enzymatic reactions of this type play a prominent role in the formation and ultimate breakdown of amino acids by living organisms.
 of the target 2-ketoacid or ketone or the reduction of the ketone and providing the mutated enzyme in a reaction mixture comprising the target 2-ketoacid or ketone under conditions sufficient to permit the formation of the desired amino acid, amine or alcohol to thereby produce the amino acid, amine or alcohol. (US 7,202,070)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Apr 1, 2007
Words:119
Previous Article:Calgene obtains United States patent.
Next Article:CEL-SCI announces issuance of United States patent for new platform technology to treat immune system-based diseases.
Topics:



Related Articles
MorphoSys widens scope of United States patent for HuCAL technology.
Roche's Taq patent held unenforceable for inequitable conduct.
Federal Court of Appeals to decide on claims for United States in fraud case against Hoffmann-La Roche.
The "Hatch" factor: is intellectual property reform on the horizon?

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles